Drug Metabolism/Pharmacology News

In a Healio video exclusive, Anu Osinusi, MD, MPH, reports that combination bulevirtide 10 mg with pegylated interferon alfa-2a for chronic hepatitis D virus infection resulted in the highest rates of undetectable HDV RNA through 48 weeks.

WASHINGTON — Glucagon-like peptide-1 receptor agonists were associated with lower risk for progression to cirrhosis and hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.

BOSTON — LPCN 1148, an oral androgen receptor agonist, improved sarcopenia, hepatic encephalopathy and other biomarkers associated with end-stage liver disease among men with advanced cirrhosis and clinical decompensation.

BOSTON — Treatment with aldafermin 3 mg appeared to be well-tolerated and significantly reduced Enhance Liver Fibrosis score after 48 weeks among patients with metabolic dysfunction-associated steatohepatitis, according to a presenter.

BOSTON — In a Healio video exclusive, Pam Vig, PhD, reports late-breaking data that show Livmarli improved liver health and maintained symptom response over 2 years among pediatric patients with progressive familial cholestasis.

BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.

BOSTON — Mortality rates were consistently lower in patients with severe alcohol-associated hepatitis treated with steroids during vs. before the COVID-19 pandemic, suggesting infection mitigation may have benefited this population.

Bulevirtide was safe and increased the proportion of patients with undetectable hepatitis D virus RNA among those in both the 2 mg and 10 mg dosage groups, according to data published in The New England Journal of Medicine.

In a Healio video exclusive, Andreas Kremer, MD, PhD, MHBA, highlights recent data on primary biliary cholangitis presented at EASL Congress, including risk factors for disease progression and seladelpar for treatment of pruritus.